Primary IgA Nephropathy (IgAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Primary IgA
Nephropathy (IgAN) Market Outlook
Thelansis’s “Primary IgA
Nephropathy (IgAN) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2025 To 2035” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Primary IgA Nephropathy (IgAN) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Primary IgA
Nephropathy (IgAN) Overview
Primary IgA nephropathy (IgAN) is the
most common primary glomerulonephritis globally, characterized by progressive
renal impairment driven by glomerular deposition of galactose-deficient IgA1
(Gd-IgA1) immune complexes. Pathogenesis follows a multi-hit model where
mesangial deposition triggers inflammation, glomerulosclerosis, and
interstitial fibrosis, presenting clinically as hematuria, hypertension, and
proteinuria. Diagnosis requires renal biopsy confirming dominant mesangial IgA
deposition on immunofluorescence. In 2026, standard management pairs
maximum-tolerated renin-angiotensin system inhibition with targeted therapies.
Frontline disease-modifying care utilizes gut-targeted, delayed-release
budesonide to suppress Gd-IgA1 production in ileal lymphoid tissue, alongside
sparsentan, a dual endothelin/angiotensin receptor antagonist that directly
addresses hemodynamic stress to reduce proteinuria. For high-risk progressive
disease, complement inhibitors targeting factor B or MASP-2 serve as critical modern
interventions to halt downstream glomerular injury.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment